Last edition
News about "Insilico Medicine"
Insilico Medicine to Present ISM6331 Phase 1 Data at ESMO 2026
Insilico Medicine will present phase 1 data for Artificial Intelligence (AI)-designed pan-TEAD inhibitor ISM6331 at ESMO 2026 in mesothelioma and advanced solid tumors.
Insilico Medicine | 28/07/2026 | By News Bureau
The collaboration between Insilico Medicine and Bora Pharmaceuticals is valued at over USD 2.5 billion if fully implemented and aims to accelerate the discovery, development and commercialisation of next-generation therapies while expanding AI adoption across the pharmaceutical value chain.
Insilico Medicine | 16/07/2026 | By News Bureau | 112
Insilico Medicine Advances AI-Discovered IPF Drug Rentosertib into Phase III Clinical Trial
Rentosertib, formerly known as ISM001-055/INS018_055, is a potentially first-in-class oral small-molecule inhibitor targeting TNIK (TRAF2 and NCK-interacting kinase) for the treatment of IPF, a progressive and irreversible lung disease with limited treatment options.
Insilico Medicine | 08/07/2026 | By Abha | 284
Insilico Medicine and Takeda Collaborate on AI Drug Discovery
Takeda and Insilico Medicine are collaborating to advance Artificial Intelligence (AI)-powered drug discovery, leveraging the Pharma.AI platform to accelerate the development of therapeutics.
Insilico Medicine | 02/07/2026 | By News Bureau | 134
Insilico Medicine and SK Biopharmaceuticals have entered an Artificial Intelligence (AI)-powered drug discovery collaboration worth up to USD 2.5 billion to develop innovative therapies for neuroimmune disorders.
Insilico Medicine | 23/06/2026 | By News Bureau | 446
Insilico Begins Phase 1 Trial of AI-Designed NLRP3 Inhibitor ISM8969
Insilico Medicine has completed first-in-human dosing of its AI-designed NLRP3 inhibitor ISM8969 in a phase 1 clinical trial. The oral, brain-penetrant therapy is being developed with Hygtia Therapeutics for chronic neuroinflammation and CNS disorders, including Parkinson’s disease, marking a key milestone in AI-driven drug development.
Insilico Medicine | 18/06/2026 | By News Bureau | 102
Insilico Medicine and Ribo Partner on AI-Powered RNA Therapeutics Development
Insilico Medicine and Ribo partner to accelerate RNA interference and oligonucleotide drug development using Artificial Intelligence (AI)I-powered discovery platforms and automated laboratory technologies.
Insilico Medicine | 13/05/2026 | By News Bureau | 186
Eli Lilly Eyes USD 2 Billion AI Drug Discovery Deal with Insilico Medicine
Eli Lilly is set to enter into a deal worth over USD 2 billion with Hong Kong-based Insilico Medicine to accelerate drug discovery using artificial intelligence, signaling a major push toward AI-driven pharmaceutical innovation.
Insilico Medicine | 30/03/2026 | By Darshana | 203
Insilico Medicine Launches PandaClaw AI Platform for Drug Discovery
Insilico Medicine launches PandaClaw AI platform to accelerate drug discovery, enabling real-time analysis, target identification and disease hypothesis generation through an intuitive natural language interface.
Insilico Medicine | 24/03/2026 | By News Bureau | 161
TaiGen Biotechnology doses first participant in Phase I trial of ISM4808, an AI-designed oral therapy from Insilico Medicine for chronic kidney disease-related anemia.
Insilico Medicine | 09/03/2026 | By News Bureau | 261
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy